REVIEW

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment [version 1; peer review: 4 approved]

Whitney Longmate¹, C Michael DiPersio ^{1,2}

¹Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA

²Department of Surgery, Albany Medical College, Albany, New York, USA

V1 First published: 31 Aug 2017, 6(F1000 Faculty Rev):1612
<https://doi.org/10.12688/f1000research.11877.1>

Latest published: 31 Aug 2017, 6(F1000 Faculty Rev):1612
<https://doi.org/10.12688/f1000research.11877.1>

Abstract

While integrins were originally discovered as cell adhesion receptors, recent studies have reinforced the concept that integrins have central roles in cancer that extend far beyond controlling cell adhesion and migration. Indeed, as transmembrane cell surface receptors that occupy a critical position at the interface of cellular and extracellular interactions and are capable of both “inside-out” and “outside-in” signaling, integrins are uniquely poised to regulate the cell’s ability to promote, sense, and react to changes in the tumor microenvironment. Moreover, integrins are present on all cell types in the tumor microenvironment, and they have important roles in regulating intercellular communication. Decades of promising pre-clinical studies have implicated certain integrins as attractive therapeutic targets in the cancer clinic. Nevertheless, results of the few clinical trials that target integrins in cancer have thus far been disappointing. Importantly, these clinical failures likely reflect the emerging complexity of individual and combinatorial integrin function within both tumor cells and other cell types of the tumor microenvironment, together with a need to explore integrin-targeting agents not just as monotherapies but also as adjuvants to more conventional radiotherapies or chemotherapies. In this review, we will examine recent advances toward understanding how integrins regulate cancer progression, including their roles in intercellular communication and modulation of the tumor microenvironment. Additionally, we will discuss factors that underlie the limited efficacy of current efforts to target integrins in the cancer clinic as well as potential strategies to overcome these challenges.

Keywords

Integrin, Cancer Therapy, Cell Signalling,

Open Peer Review

Approval Status

	1	2	3	4
version 1				
31 Aug 2017				

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Kathleen L O'Connor**, University of Kentucky, Lexington, USA
2. **Johanna Ivaska**, University of Turku, Turku, Finland
3. **Nils Cordes**, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
4. **Jonathan Jones**, Washington State University, Pullman, USA

Any comments on the article can be found at the end of the article.

Corresponding author: C Michael DiPersio (dipersm@mail.amc.edu)

Author roles: Longmate W: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; DiPersio CM: Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: The authors declare that they have no competing interests.

Grant information: We are supported by National Institutes of Health (R01CA129637, R01AR063778)

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Longmate W and DiPersio CM. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Longmate W and DiPersio CM. **Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment [version 1; peer review: 4 approved]** F1000Research 2017, 6(F1000 Faculty Rev):1612 <https://doi.org/10.12688/f1000research.11877.1>

First published: 31 Aug 2017, 6(F1000 Faculty Rev):1612 <https://doi.org/10.12688/f1000research.11877.1>

The integrin family of cell adhesion receptors

Integrins are the major receptors on the cell surface for adhesion to the extracellular matrix (ECM)¹. All members of the integrin family are heterodimeric, transmembrane glycoproteins that consist of an α and a β subunit, each with a cytoplasmic domain, a single-pass transmembrane domain, and a large extracellular domain. The dimerization of 18 α subunits and 8 β subunits in limited combinations leads to the formation of 24 different integrin pairs with distinct and often overlapping ligand-binding specificities. As a group, integrins interact with a plethora of ECM proteins, to which they bind via their extracellular domains¹. Simultaneously, integrins interact with cytoskeletal proteins via their cytoplasmic domains to mediate a physical, transmembrane linkage of the ECM to the cytoskeleton, which is critical for controlling cell shape, polarization, and motility^{1–5}.

It has long been known that integrins can also interact directly or indirectly with a wide variety of signaling effectors, thereby functioning as conduits of bidirectional signal transduction across the cell membrane^{1,2,6,7}. Indeed, integrins can regulate intracellular pathways in response to ECM binding or other extracellular cues (i.e. “outside-in” signaling) while cytoplasmic interactions can regulate the activation state of an integrin to alter its affinity for extracellular ligands (i.e. “inside-out” signaling)^{1,6,8}. Such integrin-mediated signal transduction controls a wide variety of cell functions that are important for both normal and pathological processes, including survival, proliferation, migration, ECM remodeling, and gene expression^{1,3,6}.

Integrins play critical roles in cancer progression, where they are expressed on the surfaces of both tumor cells and all other cell types present in the tumor microenvironment (TME). From within these distinct cellular compartments, integrins regulate functions of both tumor cells and stromal cells that promote tumor growth and malignant progression, including the above-mentioned cell-autonomous functions, as well as communication between different cell types of the TME (for reviews, see 9–14). Thus, as bidirectional signaling receptors that regulate both cell-mediated changes to the microenvironment and cellular responses to those changes, integrins are attractive targets for therapeutic strategies against cancer. Indeed, the general concept of targeting integrin function to treat cancer or other diseases is already well established^{10,11,15,16}. Here, we will briefly examine the current state of integrin-targeting cancer therapeutics, as well as limitations and knowledge gaps in the field that must be overcome to better exploit integrins as efficacious cancer targets. In particular, we will consider recent advances in understanding the complex roles that integrins play in modulating the TME and how this knowledge may impact the development of strategies to target integrins in the clinic, either as monotherapies or as adjuvants to conventional radiotherapies or chemotherapies.

Pro-tumorigenic integrin signaling in cancer cells

Generally, integrin-mediated signal transduction occurs through direct or indirect interaction of the integrin cytoplasmic domain with cytoplasmic signaling effectors, which in some cases may be aided through lateral interactions with other integrin-associated

cell surface proteins such as tetraspanins, caveolin, or urokinase-type plasminogen activator receptor (uPAR)^{11,17–19}. It has long been known that various intracellular signaling effectors can propagate outside-in integrin signaling, as reviewed in detail elsewhere⁶. Among the best-studied integrin-mediated signaling effectors in cancer cells are the non-receptor tyrosine kinases focal adhesion kinase (FAK) and Src. FAK and Src are both elevated in solid tumors of many origins, including breast, epidermal, and colon cancers, where they contribute to tumor growth and malignancy^{20,21}. Following integrin-mediated cell adhesion, FAK is activated by an autophosphorylation event on Y397, which generates a high-affinity binding site for the SH2 domain of Src. Once bound, Src mediates the phosphorylation of additional tyrosine residues of FAK, creating binding sites for other signaling and adaptor molecules. The activated FAK/Src scaffold thereby links integrins to downstream signaling effectors such as the Rac1 GTPase or the mitogen-activated protein kinases (MAPKs, i.e. ERK1/2, JNK, or p38).

Such signaling pathway activation can augment tumor cell migration, proliferation, survival, and gene expression, thus contributing to tumor growth and metastasis and implicating these pathways as potential therapeutic targets^{22,23}. Interestingly, results of studies in breast and squamous cell carcinoma models suggest that integrins, possibly through FAK signaling pathways, promote tumorigenesis by maintaining the pool of slow-cycling stem cells that are the primary targets of oncogenic transformation^{24,25}. Importantly, integrin signaling (in some cases through FAK) has been shown to mediate resistance to conventional therapies such as radiation and chemotherapy^{26–30}, indicating that the inhibition of integrins may prove to be most beneficial in the adjuvant setting to render other therapies more effective (as reviewed in 30). On the other hand, the stimulation of integrin signaling using agonists has also been shown to improve the response of melanoma to chemotherapy, suggesting that in some cancers the activation, rather than inhibition, of certain integrins may be beneficial, as reviewed elsewhere³¹.

Roles for integrins in the regulation of the tumor microenvironment

It is now well accepted that transformed cells, in and of themselves, are not sufficient to generate appreciable tumors with metastatic potential. Rather, cancer development additionally requires a permissive TME, and recent work in the field of cancer biology has begun to focus more on non-tumor cell components of the stroma as drivers of malignant progression (for reviews on this topic, see 32–34). As bidirectional signal transducers that are expressed on all cell types within the TME, integrins have emerged as regulators of tissue remodeling and intercellular communication between different cell types that drive tumor-supporting features of the tumor niche. In the following sections, we will focus on the roles that integrins play in modulating the TME through control over matrix remodeling and paracrine communication between distinct cell types. We will also discuss the importance of considering the complexity of these roles when attempting to circumvent the challenges associated with integrin-targeting therapies in the cancer clinic.

Integrin regulation of tumor cell invasion and metastasis

The journey of a cancer cell from the primary tumor to a distant metastatic site is an arduous one. To survive this journey, cancer cells must be able to disassociate from the primary tumor, invade adjacent stroma, intravasate the vasculature (either blood or lymph), survive circulation, then extravasate from the vasculature into a hospitable secondary site. Each step of this metastatic process selects for those tumor cells that have acquired genetic and/or epigenetic traits that allow them to survive, grow, and invade in the face of a dynamic microenvironment and to degrade or remodel basement membranes/ECM along the way³⁵.

Integrins play vital roles in cancer metastasis during every leg of the metastatic cascade^{36,37}. Indeed, integrins are critical in mediating adhesion dynamics and migration during metastasis through their ability to regulate both physical interactions with the ECM and actin cytoskeletal dynamics³⁻⁵. Certainly, roles for integrins extend well beyond cell adhesion and migration in their capacity to stimulate intracellular signaling pathways that promote proliferation and survival^{6,38}. Consistently, the upregulation or persistence of certain integrins has been generally linked to tumor invasiveness^{9,12}. For example, the expression on certain cancer cells of a number of integrin subunits, including $\alpha 3$, $\alpha 5$, $\alpha 6$, αv , $\beta 1$, $\beta 3$, and $\beta 4$, has been linked to invasive and metastatic potential³⁹⁻⁴².

With regard to the metastatic spread of cancer, the ability of integrins to control cell adhesion and migration alone is insufficient to drive invasion/metastasis, since an intact basement membrane and stromal ECM provides a physical barrier that precludes a normal cell's ability to invade local and metastatic sites. Thus, a critically important function of integrins is their additional ability to regulate matrix organization and remodeling through both proteolytic and non-proteolytic mechanisms^{12,43}. Indeed, their dual roles in modulating both cell migration and ECM remodeling makes them astute mediators of invasion and metastasis and further implicates them as viable targets for therapeutic intervention.

Numerous studies have shown that integrins can promote cell invasion through controlling the expression and/or proteolytic function of matrix metalloproteases (MMPs) and other extracellular proteases that directly degrade ECM proteins, as reviewed extensively elsewhere^{12,44}. Additionally, it is important to keep in mind that integrin-mediated modulation of MMPs and other matrix-modifying enzymes can impact tumorigenesis through the release of ECM-bound reservoirs of stored growth factors into the TME^{45,46}. In these ways, the impact of integrin-dependent protease expression/function can have profound effects on cancer progression, including by mediating intercellular communication between cells in the TME via proteolytic activation of growth factor signaling⁴⁷⁻⁴⁹.

Integrin regulation of tumor angiogenesis

Since intratumoral vessel generation is essential for appreciable tumor growth, many anti-cancer therapeutics have focused on the inhibition of endothelial cell functions required for

angiogenesis rather than directly targeting tumor cells themselves^{50,51}. It is well documented that several endothelial integrins, such as certain αv integrins and $\alpha 5\beta 1$, have complex roles in promoting tumor angiogenesis through the regulation of endothelial cell migration and proliferation⁵²⁻⁵⁴ and that simultaneous inhibition of both $\alpha v\beta 3$ and $\alpha 5\beta 1$ may be required for potent anti-angiogenic effects in some cases⁵⁵. Interestingly, another recent study showed that endothelial-specific deletion in mice of key RGD-binding integrins (i.e. $\alpha 5\beta 1$ and $\alpha v\beta 3/\beta 5$) failed to reduce tumor angiogenesis, indicating compensatory involvement of other integrins and illustrating the potential importance of targeting multiple integrins at once to inhibit tumor angiogenesis⁵⁶. Indeed, pro-angiogenic roles for the collagen-binding integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ have been described⁵⁷. Additionally, integrin $\alpha 4\beta 1$ and its ligand, vascular cell adhesion molecule-1 (VCAM-1), have been demonstrated to be important in vessel formation in both tumor and non-tumor settings^{58,59}. Other potentially important receptors on endothelial cells include the laminin-binding integrins $\alpha 3\beta 1$, $\alpha 6\beta 1$, and $\alpha 6\beta 4$ ^{60,61}; however, their roles in angiogenesis are less well explored. Results of genetic studies indicate that while endothelial $\beta 4$ promotes tumor angiogenesis⁶², the $\alpha 6$ and $\alpha 3$ integrin subunits have suppressive roles in tumor angiogenesis^{63,64}. Collectively, these findings may reflect opposite roles for $\alpha 6\beta 1$ and $\alpha 6\beta 4$ in tumor angiogenesis^{62,63}, emphasizing the importance of delineating between integrin heterodimers that share a subunit. Clearly, elucidating the complex roles of endothelial integrins in the regulation of tumor angiogenesis will require further studies that take into consideration the complex interplay between the various integrins that are expressed by the vasculature.

Some integrins on tumor cells can promote angiogenesis in a paracrine fashion by inducing the secretion of soluble factors that stimulate endothelial cells, emphasizing the importance of targeting integrins within the appropriate cellular compartment of the tumor. For example, we and others have shown that integrin $\alpha 3\beta 1$ in breast cancer cells can stimulate the expression of MMP-9⁶⁵ and Cox-2⁶⁶, indicating a role for this integrin in generating pro-angiogenic paracrine signals from tumor cells to endothelial cells. This function reflects a similar role for $\alpha 3\beta 1$ in wound epidermis, where it regulates the expression of pro-angiogenic factors that induce the paracrine stimulation of angiogenesis⁶⁷. Similarly, integrin $\alpha 6\beta 4$ has been shown to enhance the expression of vascular endothelial growth factor in breast carcinoma cells, impacting not only angiogenesis but also tumor cell survival⁶⁸. Paradoxically, as mentioned above, the expression of $\alpha 6$ or $\alpha 3$ on vascular endothelial cells has been associated with the repression of pathological angiogenesis^{63,64}, illustrating the important point that roles for specific integrins are dependent on cellular context and that these roles are not necessarily the same across distinct cellular compartments. Additionally, our recent study demonstrated that integrin $\alpha 9\beta 1$ in the epidermis can inhibit $\alpha 3\beta 1$ -dependent, paracrine stimulation of wound angiogenesis⁶⁹, indicating that cross-suppression/transdominant inhibition amongst integrins⁷⁰⁻⁷² adds another level of complexity to their roles in regulating angiogenesis that must be considered when developing integrin-targeting strategies.

Integrin regulation of intercellular communication within the TME

While it has been well established for some time that a pro-angiogenic microenvironment is critical for cancer progression, contributions from other stromal components of the TME had been underappreciated until more recently. For example, tumor-associated fibroblasts (TAFs)/cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) had been viewed largely as passive stromal constituents or bystanders to the ravaging effects of tumorigenesis and metastasis. On the contrary, critical roles for these tumor-associated stromal cells in cancer progression are now beginning to be understood^{32,34,73,74}. In the preceding section, we discussed recent evidence that certain integrins (e.g. $\alpha 3 \beta 1$) can control paracrine communication from tumor/epithelial cells to endothelial cells of the vasculature. It seems likely that such roles for integrins in intercellular communication will extend to other tumor-associated stromal cells that contribute to a tumor-permissive microenvironment.

It is now well known that TAFs/CAFs promote invasion and metastasis in several cancer types, owing in large part to their myofibroblast-like traits that generate a stiff ECM^{75–77}. There is evidence that some integrins can contribute to the generation of stiff ECM. For example, integrin $\alpha 2 \beta 1$ ligation by collagen has been shown to regulate lysyl oxidase expression in cardiac fibroblasts⁷⁸, raising the possibility that integrins on TAFs have similar roles in promoting collagen crosslinking and ECM stiffness. Furthermore, as mediators of outside-in signal transduction, integrins play important roles in mechanosensing in response to ECM stiffness⁷⁹. Indeed, matrix stiffening has been demonstrated to promote tumorigenesis, at least in part, through the activation of integrin signaling⁸⁰. This potential for integrins to both promote and respond to ECM stiffening is consistent with their central role in the “dynamic reciprocity” that has long been known to exist between cells and the ECM⁸¹.

While ECM stiffness is certainly important in tumorigenesis⁸², it has become apparent that the roles of TAFs extend beyond the promotion of a desmoplastic TME to include the generation of paracrine signals to other cell types. In some cases, the response of the target cell to signals generated by TAFs (or other mesenchymal cells of the stroma) is mediated by integrins. For example, it was recently demonstrated in a gastric cancer model that activation of CXCL12/CXCR4 signaling in TAFs promotes the clustering of $\beta 1$ integrins on tumor cells, thereby activating FAK signaling and promoting invasion⁸³. Similarly, $\beta 1$ integrins were essential in tamoxifen-resistant breast cancer cells for migration and epithelial–mesenchymal transition that was induced by signals from TAFs⁸⁴. In another example, CD151 (a tetraspanin that complexes with certain laminin-binding integrins) was recently found to mediate pro-tumorigenic responses of prostate cancer cells to signals from tumor-associated osteoblasts⁸⁵. Additionally, some tumor cell integrins may activate pro-invasive proteolytic cascades through interactions with stromal cells. For example, the interaction of integrin $\alpha 6 \beta 1$ expressed on pancreatic cancer cells with uPAR expressed on stromal fibroblasts was linked with activation in the latter cells of the uPAR–uPA–MMP-2 proteolytic cascade, thereby aiding in tumor progression⁸⁶.

TAMs have also been linked to tumor progression in particular through their ability to promote tumor angiogenesis and invasion, although the molecular underpinnings of this link have just begun to be elucidated^{87–89}. Importantly, some recent studies have implicated integrins in regulating the ability of TAMs to promote tumor progression. For example, an osteopontin-rich matrix activates TAMs in a melanoma model through ligation of integrin $\alpha 9 \beta 1$, leading to prostaglandin E2 production by TAMs that then stimulates the migration of both endothelial and cancer cells⁹⁰. Similarly, the ECM protein periostin, secreted by glioblastoma stem cells, may promote TAM recruitment to tumors via activation of $\alpha v \beta 3$ on the latter cells⁹¹. Additionally, integrin $\beta 2$ interactions have been implicated in TAM-driven dissemination of tumor cells in an *in vitro* microfluidic model of lung adenocarcinoma⁹².

Integrins as targets for anti-cancer therapy

Integrins have several characteristics that make them attractive anti-cancer targets. First, they are generally important for mediating numerous cellular functions in all stages of cancer progression, including tumor cell proliferation, survival, angiogenesis, invasion, and metastasis^{9,10,38}. Additionally, as cell surface receptors, the integrins are relatively accessible by targeting agents. Finally, the broad impact on cell function of integrin-mediated signaling indicates that targeting a single integrin, or group of integrins, might generate a combinatorial and potentially potent effect. Unfortunately, these same broad functions of integrins, which occur in both normal cells and tumor cells, also make them difficult to exploit as targets in the clinic. The remainder of this review will discuss integrin-targeting strategies and the associated challenges as we move forward in exploiting these targets more efficaciously in the cancer clinic, including their development as adjuvant targets in currently used therapies.

Clinical limitations of integrin-targeting anti-cancer therapeutics

From around the late 1990s to date, pre-clinical studies performed in a wide variety of cancer models have demonstrated that blockade or suppression of certain integrins can inhibit tumor growth or metastasis^{9,10,38,93}. Outside the cancer clinic, a number of integrin-based therapeutics have progressed to phase II or phase III clinical trials, and some have had significant benefits for patients suffering from a number of disorders, including multiple sclerosis, thrombotic complications, and inflammatory bowel disease (IBD) (for excellent reviews on this topic, see 16,31,94). As one example, vedolizumab, an antibody against integrin $\alpha 4 \beta 7$, is approved for use in the United States, Canada, and Europe for patients with either subtype of IBD (ulcerative colitis or Crohn’s disease), both of which are potential precursors to gastrointestinal malignancies^{94,95}. With regard to cancer, the concept of targeting integrins in the clinic using small molecule integrin antagonists (SMIAs) was realized when the integrin-blocking RGD mimetic Cilengitide entered clinical trials after performing well pre-clinically¹⁶. Unfortunately, the transition of Cilengitide to the cancer clinic as a monotherapy has been met with little success^{96,97}, which may be attributable in large part to several limitations. First, RGD mimetics target only the subgroup of integrins that bind RGD-containing ligands (e.g. fibronectin, tenascin, and vitronectin)¹ while failing to block

other potentially important integrins that bind non-RGD ligands such as laminins. Indeed, the laminin-binding integrins remain unexplored as clinical targets despite abundant pre-clinical evidence that supports their participation in tumor growth and metastasis^{11,15,24,66,68,98–103}. Additionally, as discussed more below, integrin-targeting agents may prove to be most effective in the cancer clinic as adjuvant therapies alongside more conventional chemotherapy or radiation treatments^{30,104–106}.

Importantly, while Cilengitide was conceptualized to target RGD-binding integrins on endothelial cells to inhibit tumor angiogenesis, perhaps through abrogation of the FAK/Src/AKT pathway^{10,107}, this approach is complicated by the presence of these integrins on additional cell types within the TME. For example, a recent study in a glioblastoma multiforme model showed that treatment with an RGD peptide also inhibits $\alpha v \beta 3$ on TAMs, restricting their recruitment to the TME⁹¹. Accordingly, moving forward it will be important to consider the potential effects of integrin-targeting agents on various cells within the tumor milieu as a whole. This approach is especially important considering that integrin expression profiles show overlap between distinct cell types and that integrins play important roles in paracrine crosstalk between different cells in the TME (discussed above).

An additional challenge is the necessity to create more directed therapeutic strategies that target key integrins within the appropriate cellular compartment(s) of the tumor. For example, while several current strategies rest on the premise of targeting endothelial cells to suppress tumor angiogenesis, other strategies that target integrins on tumor cells, or other stromal cells, remain relatively underexplored from a clinical perspective despite strong pre-clinical evidence to support this approach. Additionally, while many studies of integrin function in cancer have provided strong support for focus on the $\beta 1$ integrins as a group, more attention must be paid to the functional diversity among the 12 distinct $\alpha \beta$ heterodimers that comprise the $\beta 1$ integrin subfamily¹. Indeed, it has long been known that individual $\beta 1$ integrins have different expression patterns in many tumors¹⁰⁸, and studies have demonstrated diverse or opposing roles for distinct integrins. For example, $\alpha 2 \beta 1$ is a suppressor of metastasis in breast cancer cells¹⁰⁹, while $\alpha 3 \beta 1$ and $\alpha 6 \beta 1$ are pro-tumorigenic or pro-metastatic in breast cancer^{66,102,110,111}. Moreover, some integrins may have pro-tumorigenic roles in some cancers but anti-tumorigenic roles in other cancers, as has been shown for $\alpha 3 \beta 1$ in breast or skin versus prostate cancer, respectively^{24,66,112}, indicating that the cancer context matters in terms of predicting the effects of inhibiting a particular integrin. Indeed, there are many additional examples wherein the ability of specific $\beta 1$ integrins to perpetuate hallmarks of malignant progression can vary between different types of cancer, as recently reviewed¹¹³.

Minding the microenvironment: the future of integrin-targeting therapies

Despite the successful use of different integrin-targeting agents in pre-clinical cancer models, efforts to translate these findings to the cancer clinic have so far failed. This discordance most likely reflects the increasingly appreciated complexity of the integrin

family and the knowledge gaps in the field that must be overcome for effective exploitation of integrins as therapeutic targets. Moreover, as already mentioned, a number of studies have indicated that targeting certain integrins may sensitize cancer cells to radiotherapy or other chemotherapies^{104,105,114}, suggesting that integrin-targeting agents may be most effective in the cancer clinic when administered as adjuvants to supplement more traditional cancer therapeutics.

As discussed in the preceding sections, current literature clearly supports critical roles for integrins in cell-mediated modulation of the microenvironment that drives normal tissue remodeling or contributes to pathological tissue remodeling. It is also likely that individual integrins have distinct but collectively critical roles in controlling intercellular communication within the TME based on mounting evidence described above that integrins can regulate paracrine signals that emanate from the epithelium or stroma in normal and pathological tissue states. Therefore, identification of the full spectrum of integrins that is expressed on cells within the TME, as well as improved understanding of the combined roles that different integrins play from within these distinct cell types, will be critical for effective exploitation of integrins as anti-cancer targets.

In addition to SMIAs discussed above, there are other integrin-targeting strategies that might eventually be exploited in the cancer clinic. An example is the use of aptamers, which act as RNA ligands that can be used to antagonize the protein targets to which they are directed (for a review on the use of aptamers in targeted therapies, see 115). Interestingly, a recent study demonstrated that an aptamer directed at integrin $\alpha 6 \beta 4$ caused reduced adhesion of PC3 prostate cancer cells to laminin-332¹¹⁶. Internalization of this aptamer was also demonstrated, suggesting potential utility (i.e. beyond adhesion-blocking) for the delivery of siRNA, microRNA, or toxins to $\alpha 6 \beta 4$ -decorated cancer cells¹¹⁶. Furthermore, an aptamer that targets an epidermal growth factor receptor (EGFR)–integrin $\alpha v \beta 3$ complex was shown to impair $\alpha v \beta 3$ -dependent adhesion, as well as the matrix-induced interaction of the integrin with EGFR, thereby inhibiting growth and vasculogenic mimicry of triple-negative breast cancer cells¹¹⁷.

Another example of integrin-targeting agents that may be clinically useful are the disintegrins, which are a family of small proteins found in snake venom that can target and block the adhesion functions of specific integrins (for a review on disintegrins and their potential use in cancer therapy, see 118). Indeed, therapeutic modulation of integrin signaling through the administration of disintegrins was recently shown to elicit anti-migratory and anti-angiogenic effects in both *in vitro* and *in vivo* cancer models^{118–120}, indicating potential utility in the clinic.

In summary, while numerous studies have identified different integrin-targeting strategies, it is becoming increasingly clear that minding the TME will be critical for their effective implementation in the clinic. Moreover, it is highly likely that integrin-targeting agents will be most effective as part of a multi-combinatorial approach rather than as a monotherapy.

Conclusions

The multifaceted nature of integrin biology is increasingly evident as more and more studies reveal the wide range of both distinct and overlapping roles that integrins play, individually and cooperatively, both in normal tissue remodeling and in pathological processes such as tumor progression and metastasis. When considering integrins as possible anti-cancer targets, the vast functionality of the integrin repertoire present on cancer cells, as well as on cells of the tumor stroma, provides considerable complexity even before considering the additional complexities of a dynamic TME. Indeed, the ever-evolving TME must be better understood, and we must take into account the repertoire of integrins that are expressed by distinct cells within the TME (as well as the availability of ligands for those integrins in the TME) while also keeping in mind that the function of a specific integrin may depend on cellular context. In addition, we must consider the abilities of some integrins to regulate paracrine communication between cells as well as the potential for combinatorial and compensatory functions of different integrins.

Despite the challenges raised by these complexities, as a group the integrins remain potentially powerful anti-cancer targets worthy of further investigation and exploitation in the clinic. Whether integrins will be useful as adjuvant targets or targets of monotherapies remains to be seen. In any case, the future of exploiting integrins as anti-cancer targets begins at the bench and will likely require a holistic approach that effectively considers the above-mentioned complexities of integrin biology within the context of an evolving TME. Achieving this goal will require not only the identification of the full spectrum of integrins expressed by both tumor cells and stromal cells within the TME but also the elucidation of how different integrins function coordinately and cooperatively within these cells. Such an approach should facilitate our ability to determine the most effective integrin

combinations to target at the most appropriate stages of disease progression.

Abbreviations

CAF, cancer-associated fibroblast; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; IBD, inflammatory bowel disease; MAPK, mitogen-activated protein kinase; MMP, matrix metalloprotease; TAF, tumor-associated fibroblast; TAM, tumor-associated macrophage; TME, tumor microenvironment; uPAR, urokinase-type plasminogen activator receptor.

Competing interests

The authors declare that they have no competing interests.

Grant information

We are supported by the National Institutes of Health (R01CA129637, R01AR063778).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

The authors are grateful to Dr Sita Subbaram for critical reading of the manuscript and for important insight provided by other colleagues at Albany Medical College as well as members of the DiPersio laboratory. Research in the DiPersio laboratory is supported by NIH grants from NCI to C. M. DiPersio (R01CA129637) and from NIAMS to L. Van De Water and C. M. DiPersio (R01AR063778). We are thankful for the many researchers whose valuable contributions to the field could not be cited owing to space constraints.

References

- Hynes RO: **Integrins: bidirectional, allosteric signaling machines.** *Cell*. 2002; **110**(6): 673–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liu S, Calderwood DA, Ginsberg MH: **Integrin cytoplasmic domain-binding proteins.** *J Cell Sci*. 2000; **113**(Pt 20): 3563–71.
[PubMed Abstract](#)
- Ridley AJ, Schwartz MA, Burridge K, *et al.*: **Cell migration: integrating signals from front to back.** *Science*. 2003; **302**(5651): 1704–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Litjens SH, de Pereda JM, Sonnenberg A: **Current insights into the formation and breakdown of hemidesmosomes.** *Trends Cell Biol*. 2006; **16**(7): 376–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Delon I, Brown NH: **Integrins and the actin cytoskeleton.** *Curr Opin Cell Biol*. 2007; **19**(1): 43–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schwartz MA, Ginsberg MH: **Networks and crosstalk: integrin signalling spreads.** *Nat Cell Biol*. 2002; **4**(4): E65–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Legate KR, Fassler R: **Mechanisms that regulate adaptor binding to beta-integrin cytoplasmic tails.** *J Cell Sci*. 2009; **122**(Pt 2): 187–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Askari JA, Buckley PA, Mould AP, *et al.*: **Linking integrin conformation to function.** *J Cell Sci*. 2009; **122**(Pt 2): 165–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brakebusch C, Bouvard D, Stanchi F, *et al.*: **Integrins in invasive growth.** *J Clin Invest*. 2002; **109**(8): 999–1006.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Desgrosellier JS, Cheresh DA: **Integrins in cancer: biological implications and therapeutic opportunities.** *Nat Rev Cancer*. 2010; **10**(1): 9–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stipp CS: **Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets.** *Expert Rev Mol Med*. 2010; **12**: e3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Missan DS, DiPersio M: **Integrin control of tumor invasion.** *Crit Rev Eukaryot Gene Expr*. 2012; **22**(4): 309–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brücher BL, Jamall IS: **Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment.** *Cell Physiol Biochem*. 2014; **34**(2): 213–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hamidi H, Pietilä M, Ivaska J: **The complexity of integrins in cancer and new scopes for therapeutic targeting.** *Br J Cancer*. 2016; **115**(9): 1017–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Subbaram S, DiPersio CM: **Integrin $\alpha\beta 1$ as a breast cancer target.** *Expert Opin*

- Ther Targets*. 2011; 15(10): 1197–210.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Goodman SL, Picard M: **Integrins as therapeutic targets**. *Trends Pharmacol Sci*. 2012; 33(7): 405–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Chapman HA, Wei Y, Simon DI, *et al.*: **Role of urokinase receptor and caveolin in regulation of integrin signaling**. *Thromb Haemost*. 1999; 82(2): 291–7.
[PubMed Abstract](#)
 18. Hemler ME: **Tetraspanin functions and associated microdomains**. *Nat Rev Mol Cell Biol*. 2005; 6(10): 801–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Del Pozo MA, Schwartz MA: **Rac, membrane heterogeneity, caveolin and regulation of growth by integrins**. *Trends Cell Biol*. 2007; 17(5): 246–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Frame MC: **Src in cancer: deregulation and consequences for cell behaviour**. *Biochim Biophys Acta*. 2002; 1602(2): 114–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Summy JM, Gallick GE: **Src family kinases in tumor progression and metastasis**. *Cancer Metastasis Rev*. 2003; 22(4): 337–58.
[PubMed Abstract](#)
 22. Playford MP, Schaller MD: **The interplay between Src and integrins in normal and tumor biology**. *Oncogene*. 2004; 23(48): 7928–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Brunton VG, Frame MC: **Src and focal adhesion kinase as therapeutic targets in cancer**. *Curr Opin Pharmacol*. 2008; 8(4): 427–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. **F** Sachs N, Secades P, van Hulst L, *et al.*: **Loss of integrin $\alpha 3$ prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells**. *Proc Natl Acad Sci U S A*. 2012; 109(52): 21468–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 25. Guan JL: **Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer**. *IUBMB Life*. 2010; 62(4): 268–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Mantoni TS, Lunardi S, Al-Assar O, *et al.*: **Pancreatic stellate cells radioprotect pancreatic cancer cells through $\beta 1$ -integrin signaling**. *Cancer Res*. 2011; 71(10): 3453–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Goel HL, Sayeed A, Breen M, *et al.*: **$\beta 1$ integrins mediate resistance to ionizing radiation *in vivo* by inhibiting c-Jun amino terminal kinase 1**. *J Cell Physiol*. 2013; 228(7): 1601–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Eke I, Deuse Y, Hehlhans S, *et al.*: **β 1Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy**. *J Clin Invest*. 2012; 122(4): 1529–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Ahmed KM, Zhang H, Park CC: **NF- κ B regulates radioresistance mediated by $\beta 1$ -integrin in three-dimensional culture of breast cancer cells**. *Cancer Res*. 2013; 73(12): 3737–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. **F** Dickreuter E, Cordes N: **The cancer cell adhesion resistome: mechanisms, targeting and translational approaches**. *Biol Chem*. 2017; 398(7): 721–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 31. Tolomelli A, Galletti P, Baiula M, *et al.*: **Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators**. *Cancers (Basel)*. 2017; 9(7): pii: E78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. **F** Yuan Y, Jiang YC, Sun CK, *et al.*: **Role of the tumor microenvironment in tumor progression and the clinical applications (Review)**. *Oncol Rep*. 2016; 35(5): 2499–515.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. Zhang J, Liu J: **Tumor stroma as targets for cancer therapy**. *Pharmacol Ther*. 2013; 137(2): 200–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Marcucci F, Bellone M, Caserta CA, *et al.*: **Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads**. *Int J Cancer*. 2014; 135(6): 1265–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. **F** Lambert AW, Pattabiraman DR, Weinberg RA: **Emerging Biological Principles of Metastasis**. *Cell*. 2017; 168(4): 670–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 36. Ganguly KK, Pal S, Moulik S, *et al.*: **Integrins and metastasis**. *Cell Adh Migr*. 2013; 7(3): 251–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Seguin L, Desgrosellier JS, Weis SM, *et al.*: **Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance**. *Trends Cell Biol*. 2015; 25(4): 234–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Guo W, Giancotti FG: **Integrin signalling during tumour progression**. *Nat Rev Mol Cell Biol*. 2004; 5(10): 816–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Guan X: **Cancer metastases: challenges and opportunities**. *Acta Pharm Sin B*. 2015; 5(5): 402–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Santosh AB, Jones T, Harvey J: **A review on oral cancer biomarkers: Understanding the past and learning from the present**. *J Cancer Res Ther*. 2016; 12(2): 486–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Nisticò P, Di Modugno F, Spada S, *et al.*: **$\beta 1$ and $\beta 4$ integrins: from breast development to clinical practice**. *Breast Cancer Res*. 2014; 16(5): 459.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. **F** Carpenter BL, Chen M, Knifley T, *et al.*: **Integrin $\alpha 6 \beta 4$ Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF)**. *J Biol Chem*. 2015; 290(45): 27228–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 43. Larsen M, Artym VV, Green JA, *et al.*: **The matrix reorganized: extracellular matrix remodeling and integrin signaling**. *Curr Opin Cell Biol*. 2006; 18(5): 463–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Yue J, Zhang K, Chen J: **Role of integrins in regulating proteases to mediate extracellular matrix remodeling**. *Cancer Microenviron*. 2012; 5(3): 275–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Lu P, Weaver VM, Werb Z: **The extracellular matrix: a dynamic niche in cancer progression**. *J Cell Biol*. 2012; 196(4): 395–406.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. McCawley LJ, Matrisian LM: **Matrix metalloproteinases: they're not just for matrix anymore!** *Curr Opin Cell Biol*. 2001; 13(5): 534–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Coussens LM, Tinkle CL, Hanahan D, *et al.*: **MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis**. *Cell*. 2000; 103(3): 481–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Yu Q, Stamenkovic I: **Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis**. *Genes Dev*. 2000; 14(2): 163–76.
[PubMed Abstract](#) | [Free Full Text](#)
 49. Khan Z, Marshall JF: **The role of integrins in TGF β activation in the tumour stroma**. *Cell Tissue Res*. 2016; 365(3): 657–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Vasudev NS, Reynolds AR: **Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions**. *Angiogenesis*. 2014; 17(3): 471–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Liu S, Liu J, Ma Q, *et al.*: **Solid tumor therapy by selectively targeting stromal endothelial cells**. *Proc Natl Acad Sci U S A*. 2016; 113(28): E4079–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Hynes RO: **A reevaluation of integrins as regulators of angiogenesis**. *Nat Med*. 2002; 8(9): 918–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Demircioglu F, Hodivala-Dilke K: **$\alpha v \beta 3$ Integrin and tumour blood vessels-learning from the past to shape the future**. *Curr Opin Cell Biol*. 2016; 42: 121–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Weis SM, Cheresh DA: **αV integrins in angiogenesis and cancer**. *Cold Spring Harb Perspect Med*. 2011; 1(1): a006478.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Laurens N, Engelse MA, Jungerius C, *et al.*: **Single and combined effects of $\alpha v \beta 3$ and $\alpha 5 \beta 1$ integrins on capillary tube formation in a human fibroblastic matrix**. *Angiogenesis*. 2009; 12(3): 275–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. **F** Murphy PA, Begum S, Hynes RO: **Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors**. *PLoS One*. 2015; 10(3): e0120872.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 57. Ghatak S, Niland S, Schulz JN, *et al.*: **Role of Integrins $\alpha 1 \beta 1$ and $\alpha 2 \beta 1$ in Wound and Tumor Angiogenesis in Mice**. *Am J Pathol*. 2016; 186(11): 3011–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. **F** Garmy-Susini B, Jin H, Zhu Y, *et al.*: **Integrin $\alpha 4 \beta 1$ -VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation**. *J Clin Invest*. 2005; 115(6): 1542–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 59. Jin H, Su J, Garmy-Susini B, *et al.*: **Integrin $\alpha 4 \beta 1$ promotes monocyte trafficking and angiogenesis in tumors**. *Cancer Res*. 2006; 66(4): 2146–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Avraamides CJ, Garmy-Susini B, Varnier JA: **Integrins in angiogenesis and lymphangiogenesis**. *Nat Rev Cancer*. 2008; 8(8): 604–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Desai D, Singh P, Van De Water L, *et al.*: **Dynamic Regulation of Integrin $\alpha 6 \beta 1$ During Angiogenesis: Potential Implications for Pathogenic Wound Healing**. *Adv Wound Care (New Rochelle)*. 2013; 2(8): 401–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Nikolopoulos SN, Blaikie P, Yoshioka T, *et al.*: **Integrin $\beta 4$ signaling promotes tumor angiogenesis**. *Cancer Cell*. 2004; 6(5): 471–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Germain M, De Arcangelis A, Robinson SD, *et al.*: **Genetic ablation of the alpha**

- 6-integrin subunit in Tie1Cre mice enhances tumour angiogenesis. *J Pathol.* 2010; **220**(3): 370–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. da Silva RG, Tavora B, Robinson SD, *et al.*: Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. *Am J Pathol.* 2010; **177**(3): 1534–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Morini M, Mottolese M, Ferrari N, *et al.*: The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. *Int J Cancer.* 2000; **87**(3): 336–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Mitchell K, Svenson KB, Longmate WM, *et al.*: Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. *Cancer Res.* 2010; **70**(15): 6359–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Mitchell K, Szekeres C, Milano V, *et al.*: Alpha3beta1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3. *J Cell Sci.* 2009; **122**(Pt 11): 1778–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Chung J, Bachelder RE, Lipscomb EA, *et al.*: Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. *J Cell Biol.* 2002; **158**(1): 165–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. **F** Longmate WM, Lyons SP, Chittur SV, *et al.*: Suppression of integrin $\alpha 3 \beta 1$ by $\alpha 9 \beta 1$ in the epidermis controls the paracrine resolution of wound angiogenesis. *J Cell Biol.* 2017; **216**(5): 1473–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
70. **F** Calderwood DA, Tai V, Di Paolo G, *et al.*: Competition for talin results in trans-dominant inhibition of integrin activation. *J Biol Chem.* 2004; **279**(28): 28889–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
71. Diaz-González F, Forsyth J, Steiner B, *et al.*: Trans-dominant inhibition of integrin function. *Mol Biol Cell.* 1996; **7**(12): 1939–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. Hodivala-Dilke KM, DiPersio CM, Kreidberg JA, *et al.*: Novel roles for alpha3beta1 integrin as a regulator of cytoskeletal assembly and as a trans-dominant inhibitor of integrin receptor function in mouse keratinocytes. *J Cell Biol.* 1998; **142**(5): 1357–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. **F** Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. *Cell.* 2011; **144**(5): 646–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
74. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. *Nat Rev Cancer.* 2009; **9**(4): 239–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Kharashevili G, Simkova D, Bouchalova K, *et al.*: The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. *Cancer Cell Int.* 2014; **14**: 41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Alexander J, Cukierman E: Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. *Curr Opin Cell Biol.* 2016; **42**: 80–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Hinz B: The myofibroblast: paradigm for a mechanically active cell. *J Biomech.* 2010; **43**(1): 146–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. **F** Gao AE, Sullivan KE, Black LD 3rd: Lysyl oxidase expression in cardiac fibroblasts is regulated by $\alpha 2 \beta 1$ integrin interactions with the cellular microenvironment. *Biochem Biophys Res Commun.* 2016; **475**(1): 70–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
79. **F** Sun Z, Guo SS, Fässler R: Integrin-mediated mechanotransduction. *J Cell Biol.* 2016; **215**(4): 445–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
80. **F** Levental KR, Yu H, Kass L, *et al.*: Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell.* 2009; **139**(5): 891–906.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
81. Bissell MJ, Hall HG, Parry G: How does the extracellular matrix direct gene expression? *J Theor Biol.* 1982; **99**(1): 31–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Handorf AM, Zhou Y, Halanski MA, *et al.*: Tissue stiffness dictates development, homeostasis, and disease progression. *Organogenesis.* 2015; **11**(1): 1–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. **F** Izumi D, Ishimoto T, Miyake K, *et al.*: CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin $\beta 1$ clustering and invasiveness in gastric cancer. *Int J Cancer.* 2016; **138**(5): 1207–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
84. **F** Yuan J, Liu M, Yang L, *et al.*: Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and $\beta 1$ -integrin signaling pathway in tumor cells. *Breast Cancer Res.* 2015; **17**(1): 69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
85. **F** Grudowska A, Czaplińska D, Polom W, *et al.*: Tetraspanin CD151 mediates communication between PC3 prostate cancer cells and osteoblasts. *Acta Biochim Pol.* 2017; **64**(1): 135–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
86. He Y, Liu XD, Chen ZY, *et al.*: Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. *Clin Cancer Res.* 2007; **13**(11): 3115–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Zheng X, Turkowski K, Mora J, *et al.*: Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. *Oncotarget.* 2017; **8**(29): 48436–48452.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Goswami KK, Ghosh T, Ghosh S, *et al.*: Tumor promoting role of anti-tumor macrophages in tumor microenvironment. *Cell Immunol.* 2017; **316**: 1–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Guo Q, Jin Z, Yuan Y, *et al.*: New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy. *J Immunol Res.* 2016; **2016**: 9720912.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Kale S, Raja R, Thorat D, *et al.*: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via $\alpha 9 \beta 1$ integrin. *Oncogene.* 2014; **33**(18): 2295–306.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. **F** Zhou W, Ke SQ, Huang Z, *et al.*: Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. *Nat Cell Biol.* 2015; **17**(2): 170–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
92. Bai J, Adriani G, Dang T, *et al.*: Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and $\beta 2$ integrin interactions. *Oncotarget.* 2015; **6**(28): 25295–307.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Yamada S, Bu X, Khankaldyyan V, *et al.*: Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. *Neurosurgery.* 2006; **59**(6): 1304–12; discussion 1312.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Ley K, Rivera-Nieves J, Sandborn WJ, *et al.*: Integrin-based therapeutics: biological basis, clinical use and new drugs. *Nat Rev Drug Discov.* 2016; **15**(3): 173–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Singh H, Grewal N, Arora E, *et al.*: Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. *J Nat Sci Biol Med.* 2016; **7**(1): 4–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. Weller M, Nabors LB, Gorlia T, *et al.*: Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. *Oncotarget.* 2016; **7**(12): 15018–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Paolillo M, Serra M, Schinelli S: Integrins in glioblastoma: Still an attractive target? *Pharmacol Res.* 2016; **113**(Pt A): 55–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. **F** Stewart RL, O'Connor KL: Clinical significance of the integrin $\alpha 6 \beta 4$ in human malignancies. *Lab Invest.* 2015; **95**(9): 976–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
99. Weaver VM, Lelièvre S, Lakin JN, *et al.*: beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. *Cancer Cell.* 2002; **2**(3): 205–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Goel HL, Gritsko T, Pursell B, *et al.*: Regulated splicing of the $\alpha 6$ integrin cytoplasmic domain determines the fate of breast cancer stem cells. *Cell Rep.* 2014; **7**(3): 747–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Davis TL, Cress AE, Dalkin BL, *et al.*: Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. *Prostate.* 2001; **46**(3): 240–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. **F** Yang XH, Richardson AL, Torres-Arzuay MI, *et al.*: CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. *Cancer Res.* 2008; **68**(9): 3204–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
103. Mercurio AM, Bachelder RE, Chung J, *et al.*: Integrin laminin receptors and breast carcinoma progression. *J Mammary Gland Biol Neoplasia.* 2001; **6**(3): 299–309.
[PubMed Abstract](#) | [Publisher Full Text](#)
104. **F** Eke I, Zscheppang K, Dickreuter E, *et al.*: Simultaneous $\beta 1$ integrin-EGFR targeting and radiosensitization of human head and neck cancer. *J Natl Cancer Inst.* 2015; **107**(2): pii: djv419.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
105. Nam JM, Onodera Y, Bissell MJ, *et al.*: Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. *Cancer Res.* 2010; **70**(13): 5238–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. Sorensen BH, Rasmussen LJ, Broberg BS, *et al.*: Integrin β_1 , Osmosensing, and

- Chemoresistance in Mouse Ehrlich Carcinoma Cells.** *Cell Physiol Biochem.* 2015; **36**(1): 111–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Oliveira-Ferrer L, Hauschild J, Fiedler W, *et al.*: **Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.** *J Exp Clin Cancer Res.* 2008; **27**: 86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 108. Mizejewski GJ: **Role of integrins in cancer: survey of expression patterns.** *Proc Soc Exp Biol Med.* 1999; **222**(2): 124–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
 109. Ramirez NE, Zhang Z, Madamanchi A, *et al.*: **The $\alpha_v\beta_3$ integrin is a metastasis suppressor in mouse models and human cancer.** *J Clin Invest.* 2011; **121**(1): 226–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 110. Wang H, Fu W, Im JH, *et al.*: **Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis.** *J Cell Biol.* 2004; **164**(6): 935–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 111. Zhou B, Gibson-Corley KN, Herndon ME, *et al.*: **Integrin $\alpha 3\beta 1$ can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma.** *Mol Cancer Res.* 2014; **12**(1): 143–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 112. Varzavand A, Hacker W, Ma D, *et al.*: **$\alpha 3\beta 1$ Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.** *Cancer Res.* 2016; **76**(22): 6577–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 113. Blandin AF, Renner G, Lehmann M, *et al.*: **$\beta 1$ Integrins as Therapeutic**
- Targets to Disrupt Hallmarks of Cancer.** *Front Pharmacol.* 2015; **6**: 279.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
114. Campbell MR, Zhang H, Ziaee S, *et al.*: **Effective treatment of HER2-amplified breast cancer by targeting HER3 and $\beta 1$ integrin.** *Breast Cancer Res Treat.* 2016; **155**(3): 431–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 115. Cerchia L, Giangrande PH, McNamara JO, *et al.*: **Cell-specific aptamers for targeted therapies.** *Methods Mol Biol.* 2009; **535**: 59–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 116. Berg K, Lange T, Mittelberger F, *et al.*: **Selection and Characterization of an $\alpha 6\beta 4$ Integrin blocking DNA Aptamer.** *Mol Ther Nucleic Acids.* 2016; **5**(3): e294.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 117. Camorani S, Crescenzi E, Gramanzini M, *et al.*: **Aptamer-mediated impairment of EGFR-integrin $\alpha v\beta 3$ complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.** *Sci Rep.* 2017; **7**: 46659.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 118. Arruda Macêdo JK, Fox JW, de Souza Castro M: **Disintegrins from snake venoms and their applications in cancer research and therapy.** *Curr Protein Pept Sci.* 2015; **16**(6): 532–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 119. Minea R, Helchowski C, Rubino B, *et al.*: **Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.** *Toxicol.* 2012; **59**(4): 472–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 120. Saviola AJ, Burns PD, Mukherjee AK, *et al.*: **The disintegrin tzabcanin inhibits adhesion and migration in melanoma and lung cancer cells.** *Int J Biol Macromol.* 2016; **88**: 457–64.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Jonathan Jones**
School of Molecular Biosciences, Washington State University, Pullman, WA, 99164-7520, USA
Competing Interests: No competing interests were disclosed.
2. **Nils Cordes**
National Center for Radiation Research in Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
Competing Interests: No competing interests were disclosed.
3. **Johanna Ivaska**
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
Competing Interests: No competing interests were disclosed.
4. **Kathleen L O'Connor**
Markey Cancer Center, University of Kentucky, Lexington, USA
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research